Codexis and Matrix Laboratories enter into partnership for development and commercialization of novel process
Advertisement
Codexis announced it has signed an agreement with Matrix Laboratories (Matrix), a leading provider of active pharmaceutical ingredients (APIs) to the global pharmaceutical industry, for the development and commercialization of the API for a high-value pharmaceutical product.
Codexis will employ its proprietary pharmaceutical process re-engineering technology platform to develop a novel synthetic process for the product via a Codexis Thoroughbred(TM) biocatalyst. The process will be transferred to Matrix for scale-up and manufacturing. Under the terms of the collaboration, Codexis will receive research and development funding, milestone payments and a royalty on net sales of the product. Matrix will receive exclusive manufacturing and marketing rights to the novel process. Further financial terms were not disclosed.